Salomon Smith Barney Inc., CIBC World Markets Corp. and ING Barings LLC are managers of the underwriting syndicate which will offer the shares to the public. Avigen is a leader in the development of gene therapy products for the treatment of inherited diseases.
AAV vectors are a relatively new system for gene therapy.
Avigen believes its AAV vectors can be used to deliver genes for the treatment of hemophilia B and hemophilia A, Gaucher disease, hereditary emphysema and. -Thalassemia. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any State in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State.